论文部分内容阅读
Great achievements have been made in management of atrial fibrillation (AF),including drug therapy,catheter ablation and percutaneous closure of left atrial appendage in recent years.The development of new generation anticoagulation drugs will hopefully be a landmark in the management of AF.It was shown in RELY study that dabigatran,a direct competitive inhibitor of thrombin,was associated with lower rates of stroke and systemic embolism but similar rates of major hemorrhage as compared with warfarin.ATHENA study revealed that dronedarone reduced the incidence of stroke and hospitalization due to cardiovascular events or death in patients with AF.Dmnedarone,a new antiarrhythmie drug,was approved by FDA for management of AF.Catheter ablation of AF has emerged as a mainstream therapy.it was shown in a recent study that the incidence of stroke in the patients underwent Successful ablation was only 0.07%.This study estabolished the fact that Successful catheter ablation of AF could improve the outcome of patients with AF.In the field of device therapy of AF,PROTECT-AF confirmed that percutaneous closure of left atrial appendage was not inferior to warfarin with regard to prevention of stroke in patients with AF.